Onconetix, Inc.
ONCO
Positions held
Your positionsONCO isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $3.43M | Enterprise value | -$3.17M | Trailing P/E | 0.00 | Forward P/E | -0.77 |
| PEG | — | Price / book | 0.18 | Beta | 2.61 | Dividend yield | 0.00% |
| Revenue growth | -83.9% | Earnings growth | — | Gross margin | 80.4% | Operating margin | -131.1% |
| Profit margin | 0.0% | ROE | -105.2% | ROA | -27.0% | Debt / equity | 0.01 |
| Current ratio | 2.21 | Free cash flow | -$5.92M | Analyst recommendation | none | Mean target | — |
| 52w high | $207.00 | 52w low | $0.58 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.3M | $0.3M | $0.1M | — |
| Op margin | -13112.1% | -9748.8% | -422.1% | -681.5% | -1259.6% | — |
| Net income | -$2.9M | -$4.2M | $5.7M | -$8.8M | -$2.4M | — |
| Gross margin | 25.1% | -7.7% | 81.6% | 88.6% | 66.2% | — |
| Gross profit | $0.0M | -$0.0M | $0.2M | $0.3M | $0.1M | — |
| Operating income | -$2.2M | -$2.1M | -$1.3M | -$2.1M | -$1.3M | — |
- Revenue -20% vs prior quarter ($0.0M vs $0.0M).
- Gross margin 25.1% (was -7.7% prior quarter).
- Operating margin compressed to -13112.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.8M | $2.5M | $0.1M | $0.0M | — |
| Op margin | -778.2% | -409.3% | -30526.4% | — | — |
| Net income | -$14.0M | -$58.7M | -$37.4M | -$13.4M | — |
| Gross margin | 77.6% | 41.8% | -1927.9% | — | — |
| Gross profit | $0.6M | $1.1M | -$1.1M | $0.0M | — |
| Operating income | -$6.3M | -$10.3M | -$17.8M | -$13.5M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · BC-Most Active Stocks
2026-09-25 · BC-Most Active Stocks
2026-09-24 · SRX Global Makes Investment in Onconetix
2026-09-14 · CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
2026-09-14 · Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
2026-09-14 · Realbotix LLC Announces Bridge Loan from Onconetix
2026-08-05 · Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG
Price (daily)
Full chart · RSI · MACD · patterns